Silexion Implements 1-for-10 Reverse Split Ahead of May 29 Listing
SLXN•Silexion Therapeutics will implement a 1-for-10 reverse share split effective after market close on May 28, with split-adjusted trading beginning on May 29, 2026. The move aims to meet Nasdaq’s minimum bid price listing requirement, strengthen its capital structure and support its upcoming Phase 2/3 trial of SIL204 for pancreatic cancer.
1. Reverse Split Details
Silexion will effect a 1-for-10 reverse share split after market close on May 28, 2026, consolidating every ten outstanding ordinary shares into one. Trading of split-adjusted shares will begin on the Nasdaq Capital Market at market open on May 29, 2026 under the existing listing symbol.
2. Nasdaq Compliance and Capital Structure
The reverse split is intended to satisfy Nasdaq’s minimum bid price requirement and preserve the company’s continued listing. It will raise the per-share trading range, reduce volatility and broaden the investor base to improve flexibility for future equity financings.
3. Shareholder Adjustments
Shareholders holding shares in book-entry form or through a broker will see their holdings automatically adjusted to reflect the new one-for-ten ratio. Fractional share entitlements will be rounded up to the next whole share, and no action is required by shareholders.
4. Clinical Program Support
This capital-structure adjustment is timed to support Silexion’s strategic growth initiatives, including equity financing flexibility, as the company prepares to initiate its Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer during the second quarter.
